Cynthia Retna Sartika

Cynthia Retna Sartika

Auto-generated profile, based on publicly available information

Cynthia Retna Sartika

Departement of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy Universitas Padjadjaran https://ror.org/00xqf8t64

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2026 in Cell Transplantation
Verified
Journal Article
Open access
CSCynthia Retna Sartika
Cynthia Retna Sartika
RHRima Haifa
Rima Haifa
ACAngliana Chouw
Angliana Chouw
AHAtikah Anwar Hasibuan
Atikah Anwar Hasibuan
Karina KalasubaKarina Kalasuba
Karina Kalasuba
LULestari Mahardika Urbaningrum
Lestari Mahardika Urbaningrum
Mesenchymal stromal cell (MSC)–based therapies have demonstrated broad therapeutic potential across inflammatory, degenerative, and neurological disorders; however, clinical outcomes remain highly variable, largely due to heterogeneity in cell source, dosing strategies, routes of administration, treatment timing, and patient-specific factors. This review evaluates how MSC dose and delivery route influence clinical efficacy and safety, and whether specific administration routes require tailored dosing strategies. A systematic literature search of PubMed, Scopus, Web of Science, and the Cochrane Library (2015–2025) identified 29 eligible clinical trials employing intravenous (n = 13), intrathecal (n = 10), intramuscular (n = 4), intranasal (n = 1), and multi-route (n = 1) administration, with doses ranging from 2 × 10 5 cells/kg body weight to fixed doses exceeding 1 × 10 8 cells. Intravenous delivery was predominantly used for systemic indications but was limited by pulmonary first-pass sequestration, whereas intrathecal and intranasal routes enhanced central nervous system targeting and intramuscular administration supported prolonged local persistence and paracrine activity. Although MSC therapy was generally well tolerated across studies, substantial outcome variability underscores the need for harmonized frameworks for dose selection, route optimization, and manufacturing consistency. This review highlights critical gaps in dose–route optimization and supports the development of standardized clinical guidelines and advanced strategies, including MSC priming and engineering, to improve therapeutic predictability and translational success.

1 January 2026 in Obstetrics and Gynecology International
Verified
Journal Article
Open access
BHBinarwan Halim
Binarwan Halim
CSCynthia Retna Sartika
Cynthia Retna Sartika
LSLaura Agnes Edessa Sibuea
Laura Agnes Edessa Sibuea
CWCarine Annabella Widjaja
Carine Annabella Widjaja
DNDiana Novia
Diana Novia
Karina KalasubaKarina Kalasuba
Karina Kalasuba
Background: Suboptimal sperm quality often poses a challenge to successful fertilization. This study hypothesizes that secretome could enhance sperm quality and increase the likelihood of successful pregnancy. This research aims to assess the impact of secretome on various sperm quality parameters, including concentration, motility, and DNA fragmentation, while considering patient‐related factors such as age, duration of abstinence, and body mass index (BMI). Method: An analysis involving 45 patients enrolled in the pregnancy program at Halim Fertility Center, Stella Maris Women’s and Children’s Hospital, Indonesia, from April to September 2023 was conducted. Semen samples from these patients were subjected to the swim‐up method and divided into two groups: Group A, which underwent swim‐up without secretome, and Group B, which underwent swim‐up with the addition of secretome. DNA fragmentation analysis was performed on the sperm swim‐up results from both groups. The sperm analysis data obtained before swim‐up (pretreatment) with those of Group A and Group B were compared. Result: The demographic data revealed an average age of 37.67 ± 5.36 years, abstinence duration of 4.00 ± 1.15 days, and BMI of 28.20 ± 3.49 kg/m 2 among the patients. No significant difference was observed in sperm concentration between pretreatment, Group A, and Group B (mil/mL) (36.2 ± 18.5; 36.3 ± 18.4; 36.6 ± 19.3). However, a significant difference was found in the rapid progressive motility of sperm across pretreatment, Group A, and Group B (%) (0.48 ± 1.32; 13.7 ± 8.3; 17 ± 8.3), as well as a significant reduction in DNA fragmentation in Group B compared to Group A (%) (3.48 vs. 4.39). Conclusions: The findings suggest that secretome enhances rapid progressive motility and reduces DNA fragmentation rates without affecting sperm concentration.

13 March 2026 in Orthopedic Reviews
Verified
Journal Article
Open access
PDF file
YAYanuarso
Yanuarso
DDDitta Kalyani Devi
Ditta Kalyani Devi
KLKeri Lestari
Keri Lestari
CSCynthia Retna Sartika
Cynthia Retna Sartika
Karina KalasubaKarina Kalasuba
Karina Kalasuba
LULestari Mahardika Urbaningrum
Lestari Mahardika Urbaningrum
Background: Osteoarthritis (OA) is a degenerative joint disorder that causes pain, stiffness, and functional impairment. Conventional treatments relieve symptoms but do not restore cartilage, limiting long-term efficacy. Cell-based therapies, including mesenchymal stem cells (MSCs) and MSC-derived secretome, have emerged as promising strategies for cartilage regeneration. Object: This study aimed to assess the therapeutic effects of UC-MSCs and UC-MSC-derived secretome in OA patients through both clinical outcomes and synovial fluid (SF) analyses. Methods: Eligible participants were divided into two groups; group who underwent arthroscopy and group who did not. All the participants received an intra-articular injection consisting of an initial 2 mL dose of UC-MSC secretome, followed by 10 million UC-MSCs, and two additional 2 mL doses of secretome administered biweekly. Synovial fluid samples were collected at baseline and 12 weeks post-treatment, centrifuged to obtain the supernatant, and analyzed for inflammatory cytokines and matrix-degrading markers using multiplex and ELISA assays. Clinical evaluations were conducted at 6- and 12-months post-treatment. Result: The results showed that UC-MSC therapy significantly improved functional outcomes in patients with knee osteoarthritis, as indicated by WOMAC scores up to six months. In vitro studies showed similar results, where co-culture of osteoarthritic synovial fluid-derived MSCs with UC-MSCs or UC-MSC secretome enhanced proliferation and differentiation while rapidly reducing pro-inflammatory cytokines (IL-1β, IFN-γ, IL-6, IL-12p70, IL-17A, IL-18) and MMPs (MMP1, MMP7, MMP13). Conclusion: Our findings support a two-stage therapeutic strategy in which UC-MSC secretome first alleviates inflammation, followed by UC-MSCs to promote cartilage regeneration. Post-injection rehabilitation or repeated MSC dosing may further enhance treatment efficacy, highlighting the potential of MSC-based therapies for knee OA management.